As power shifts hands in Washington, a top analyst predicts an unavoidable war over rising drug prices

The drug industry has two powerful reasons for bucking President Donald Trump’s campaign to cap and lower drug prices. As Bernstein’s Ronny Gal sees it, they have to keep drug prices moving upward to meet Wall Street’s expectations on their numbers.